Xenetic Biosciences Inc. (NASDAQ:XBIO) began an open-label, U.S. Phase II trial to evaluate XBIO-101 (sodium cridanimod) plus progestin therapy in about 72 patients with recurrent or persistent endometrial cancer not amenable to surgical treatment or...

Xenetic will purchase worldwide rights to develop and commercialize Virexxa from Kevelt and Pharmsynthez for 111.5 million shares of Xenetic, valued at $93.7 million based on Xenetic close of $0.84 on Nov. 13, the last...

Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass.   Business: Drug delivery   Date completed: 2015-07-08   Type: Private placement of senior convertible notes   Raised: $3 million   Shares outstanding prior: 150 million   Investor: Pharmsynthez...

Xenetic said Pharmsynthez completed dosing in a 3-part, open-label, Russian Phase I/IIa trial evaluating MyeloXen in 26 subjects. The first part enrolled 6 healthy volunteers, while the second and third parts enrolled 10 patients each...

A placebo-controlled, Russian Phase I trial in 12 healthy volunteers showed that single doses of 0.25, 0.75 and 1.5 mg/kg subcutaneous PSA-Oxyntomodulin were well tolerated. The trial was conducted by Pharmsynthez, which has exclusive rights...

An open-label, Russian Phase I trial in 12 healthy volunteers showed that once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez, which conducted the trial, plans to start...

Pharmsynthez and Rafarma have agreed to a production plan under which Rafarma's facilities will manufacture Pharmsynthez's products. Rafarma said the plan would double manufacturing capacity. The deal will close after Pharmsynthez's technical audit of Rafarma's...

Xenetic said Pharmsynthez began a placebo-controlled, Russian Phase I trial to evaluate 3 dose levels of PSA-Oxyntomodulin in 12 healthy volunteers. Xenetic (formerly Lipoxen plc ) has rights to develop and commercialize the product outside of...

Xenetic said Pharmsynthez began an open-label, Russian Phase I trial to evaluate 2,500 and 5,000 units of PulmoXen in 12 healthy volunteers. Xenetic (formerly Lipoxen plc ) has rights to develop and commercialize PulmoXen outside of...

Opko acquired about a 10% stake in Russian pharmaceutical company Pharmsynthez. Opko said it made the investment alongside of Russian nanotechnology fund Rusnano, which invested about RUR820 million ($26.2 million). Opko said it and Rusnano...